Last reviewed · How we verify

Self-Administered Nitrous Oxide

Beth Israel Deaconess Medical Center · FDA-approved active Small molecule

Nitrous oxide acts as a dissociative anesthetic and analgesic by antagonizing N-methyl-D-aspartate (NMDA) receptors in the central nervous system.

Nitrous oxide acts as a dissociative anesthetic and analgesic by antagonizing N-methyl-D-aspartate (NMDA) receptors in the central nervous system. Used for Acute pain relief and anxiolysis in medical settings, Procedural sedation and analgesia.

At a glance

Generic nameSelf-Administered Nitrous Oxide
Also known asnitrous oxide
SponsorBeth Israel Deaconess Medical Center
Drug classInhalational anesthetic and analgesic
TargetNMDA receptor antagonist
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Nitrous oxide (N2O) is an inhalational gas that produces anesthesia and analgesia through non-competitive antagonism of NMDA glutamate receptors. It also enhances inhibitory GABAergic neurotransmission and may modulate monoamine systems. When self-administered in controlled settings, it provides rapid onset analgesia and mild sedation with quick recovery upon discontinuation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: